Autologous memory lymphocyte not checked
Newish Technology (Beijing) Co., Ltd.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.”In the company’s words, NCT05352646 on ClinicalTrials.gov
- Tested for
- Hepatocellular Carcinoma
- Main trialPhase 1
- “This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and efficacy of autologous memory lymphocyte therapy (NewishT) in patients with hepatocellular carcinoma at high risk of recurrence after radical resection.”In the company’s words, NCT05352646 on ClinicalTrials.gov
- Other names
- Low-dose group · High-dose group
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 30 Jun 2024 | NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026